Quillichew er info?

What is Quillichew ER?

Quillichew ER is a once-daily extended-release formulation of the bronchodilator albuterol sulfate, used for the relief of bronchospasm in adults and children 4 years of age and older with asthma. It is designed to provide 12 hours of relief. [1]

How does Quillichew ER work?

As a beta-2 adrenergic agonist, albuterol sulfate in Quillichew ER works by relaxing the smooth muscles in the airways, which helps to open them up and make breathing easier. [1]

When can Quillichew ER be used?

Quillichew ER is indicated for patients 4 years of age and older who have asthma. It is intended for maintenance treatment of bronchospasm and not for acute relief. [1]

What is the difference between Quillichew ER and other albuterol inhalers?

Quillichew ER is an extended-release chewable tablet, offering a 12-hour duration of action with a once-daily dosing schedule. This differs from standard albuterol inhalers, which are typically short-acting, providing rapid but temporary relief of acute bronchospasm and requiring dosing every 4-6 hours. [1]

What are the potential side effects of Quillichew ER?

Common side effects reported include upper respiratory tract infection, fever, nasopharyngitis, nausea, and vomiting. More serious potential side effects can include paradoxical bronchospasm, cardiovascular effects like increased heart rate and blood pressure, and allergic reactions. [1]

Are there any specific patient populations for whom Quillichew ER is not recommended?

Quillichew ER should be used with caution in patients with hypersensitivity to albuterol sulfate, cardiovascular disorders, diabetes, hyperthyroidism, or seizure disorders. It is not intended for use in patients with only mild asthma or as sole therapy for patients with poorly controlled asthma. [1]

When does the patent for Quillichew ER expire?

Patent information for pharmaceutical products like Quillichew ER is tracked by specialized databases. For detailed patent expiry dates and related information, resources such as DrugPatentWatch.com are available. [2]